FDA Announcement on Transvaginal Mesh for Prolapse
Due to the recently FDA announcement on transvaginal mesh for prolapse on April 16, 2019, we thought it was important to reach out to patients and women on what this all means. Please see the link for more information from the FDA:
We at the UCA Women’s Center were shocked and surprised by the FDA’s announcement. The main reason the FDA decided to pull transvaginal mesh from the market was the fact that it currently has not been shown to be superior to using a women’s own tissue. Mesh used for midurethral slings for the treatment of stress urinary incontinence and mesh placed abdominally for sacrocolpopexy are safe and effective and have not been pulled from the market.
This announcement does not mean that these meshes have been “recalled”. If you have had one of these meshes placed and are not having any issues there is nothing that needs to be done. If you are having any issues that you feel could be related to transvaginal mesh, then we at UCA Women’s Center will be happy to evaluate you.
UCA Women’s Center health care providers are trained in female pelvic health and surgeries. If you have prolapse and need or would benefit from surgery, we offer both native tissue (using your own tissue) or robotic assisted abdominal sacrocolpopexy for the treatment of pelvic organ prolapse.